VB-111: Targeting Cancer
VBL’s lead product candidate from our oncology program, VB-111, is a first-in class targeted anti-cancer gene-based biologic agent that we are developing for solid tumor indications, with clinical trials in rGBM, ovarian cancer and thyroid cancer.
VB-111 is administered systemically and is both tissue- and condition-specific, allowing for targeted and limited gene expression in endothelial cells, the thin layer of cells that lines the interior surface of blood vessels undergoing angiogenesis.
Following the successful completion of a Phase 1/2, VB-111 has been advanced into tumor specific, repeat-dose trials including:
- Recurrent Glioblastoma (rGBM) – VBL Therapeutics’ pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA. The trial is conducted in the US, Canada and Israel.
- Ovarian cancer – VBL completed a Phase 1/2 clinical trial in recurrent ovarian cancer, which combined VB-111 therapy with paclitaxel, a common chemotherapeutic agent used to treat ovarian cancer, to evaluate safety and efficacy in this indication. The company expects to launch a Phase 3 study in platinum-resistant Ovarian Cancer in the second half of 2017.
- Differentiated Thyroid cancer – VBL conducted an open-label Phase 2 clinical trial to evaluate safety and efficacy of VB-111 in advanced, recently progressive differentiated thyroid cancer that is unresponsive to radioactive iodine.
- Lung cancer – VBL plans to conduct an exploratory study of VB-111 in combination with a checkpoint inhibitor (immuno-therapy) in non-small-cell lung cancer. The trial launch is expected towards year-end 2017.